NO20091190L - Fremgangsmater og sammensetninger for behandling av kreft - Google Patents

Fremgangsmater og sammensetninger for behandling av kreft

Info

Publication number
NO20091190L
NO20091190L NO20091190A NO20091190A NO20091190L NO 20091190 L NO20091190 L NO 20091190L NO 20091190 A NO20091190 A NO 20091190A NO 20091190 A NO20091190 A NO 20091190A NO 20091190 L NO20091190 L NO 20091190L
Authority
NO
Norway
Prior art keywords
cancer
methods
compositions
treatment
hydroxylase
Prior art date
Application number
NO20091190A
Other languages
English (en)
Norwegian (no)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Cougar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091190(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cougar Biotechnology Inc filed Critical Cougar Biotechnology Inc
Publication of NO20091190L publication Critical patent/NO20091190L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20091190A 2006-08-25 2009-03-20 Fremgangsmater og sammensetninger for behandling av kreft NO20091190L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
NO20091190L true NO20091190L (no) 2009-03-20

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20091190A NO20091190L (no) 2006-08-25 2009-03-20 Fremgangsmater og sammensetninger for behandling av kreft
NO20200775A NO20200775A1 (no) 2006-08-25 2020-07-01 Fremgangsmåter og sammensetninger for behandling av kreft

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20200775A NO20200775A1 (no) 2006-08-25 2020-07-01 Fremgangsmåter og sammensetninger for behandling av kreft

Country Status (21)

Country Link
EP (3) EP2478907B1 (xx)
JP (9) JP2010501575A (xx)
KR (4) KR20090059126A (xx)
CN (2) CN104306977A (xx)
AU (6) AU2007287098C1 (xx)
CA (1) CA2661422C (xx)
CY (2) CY1115477T1 (xx)
DK (2) DK2478907T3 (xx)
ES (2) ES2428634T3 (xx)
HK (1) HK1131577A1 (xx)
HR (2) HRP20130961T1 (xx)
HU (1) HUE054495T2 (xx)
IL (3) IL197211A0 (xx)
LT (1) LT2478907T (xx)
NO (2) NO20091190L (xx)
NZ (1) NZ597830A (xx)
PL (2) PL2478907T3 (xx)
PT (2) PT2061561E (xx)
RS (2) RS52956B (xx)
SI (2) SI2061561T1 (xx)
WO (1) WO2008024484A1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
CL2008003198A1 (es) * 2007-10-29 2009-12-18 Takeda Pharmaceuticals Co Composicion farmaceutica que comprende un inhibidor de esteroide c17,20 liasa; y uso para el tratamiento de cancer de prostata independiente de androgenos.
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
HUE036513T2 (hu) 2011-04-01 2018-07-30 Genentech Inc AKT inhibitor vegyület és abirateron kombinációja terápiás kezelésekben való alkalmazásra
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
JP2015518888A (ja) * 2012-06-06 2015-07-06 ノバルティス アーゲー 腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20160082019A1 (en) * 2013-04-04 2016-03-24 Exelixis, Inc. Drug Combinations to Treat Cancer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN106061481B (zh) * 2013-10-01 2019-08-16 诺华股份有限公司 用于治疗癌症的雄激素受体抑制剂与akt抑制剂的组合
RU2016116915A (ru) * 2013-10-01 2017-11-13 Новартис Аг Комбинация
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CA3031705A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with niraparib
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2742331B2 (ja) 1992-03-31 1998-04-22 ブリテイツシユ・テクノロジー・グループ・リミテツド 癌治療に有用な１７位置換ステロイド
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
DK1276482T3 (da) * 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
SI1556058T1 (sl) 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu

Also Published As

Publication number Publication date
JP2020114851A (ja) 2020-07-30
CN101528308A (zh) 2009-09-09
JP2021038252A (ja) 2021-03-11
JP2015110577A (ja) 2015-06-18
AU2021201649A1 (en) 2021-04-08
HUE054495T2 (hu) 2021-09-28
KR20200125776A (ko) 2020-11-04
LT2478907T (lt) 2021-06-25
CN104306977A (zh) 2015-01-28
JP2019059750A (ja) 2019-04-18
AU2018271331A1 (en) 2018-12-20
NZ597830A (en) 2013-02-22
EP2478907A2 (en) 2012-07-25
CY1124221T1 (el) 2022-05-27
ES2428634T3 (es) 2013-11-08
KR20150108946A (ko) 2015-09-30
JP2012082215A (ja) 2012-04-26
HK1131577A1 (en) 2010-01-29
HRP20130961T1 (hr) 2013-11-22
JP2017052791A (ja) 2017-03-16
EP2478907A3 (en) 2012-08-01
JP2010501575A (ja) 2010-01-21
JP2022185091A (ja) 2022-12-13
IL257681A (en) 2018-04-30
IL197211A0 (en) 2009-12-24
AU2017201764A1 (en) 2017-04-06
AU2015221447B2 (en) 2016-12-15
IL227746A0 (en) 2013-09-30
PT2478907T (pt) 2021-05-26
PL2478907T3 (pl) 2021-10-25
DK2478907T3 (da) 2021-05-25
SI2061561T1 (sl) 2013-11-29
JP2018065859A (ja) 2018-04-26
ES2869343T3 (es) 2021-10-25
RS62034B1 (sr) 2021-07-30
HRP20210670T1 (hr) 2021-06-11
EP2061561A1 (en) 2009-05-27
JP6740497B2 (ja) 2020-08-12
AU2007287098B2 (en) 2013-08-15
RS52956B (en) 2014-02-28
JP6053279B2 (ja) 2016-12-27
JP6445123B2 (ja) 2018-12-26
KR20090059126A (ko) 2009-06-10
AU2007287098A1 (en) 2008-02-28
EP2061561B1 (en) 2013-07-10
EP2478907B1 (en) 2021-04-14
CA2661422A1 (en) 2008-02-28
EP3804730A1 (en) 2021-04-14
AU2022206696A1 (en) 2022-08-11
NO20200775A1 (no) 2009-03-20
PL2061561T3 (pl) 2013-12-31
AU2015221447A1 (en) 2015-09-17
DK2061561T3 (da) 2013-10-07
CA2661422C (en) 2017-06-27
PT2061561E (pt) 2013-10-09
AU2007287098C1 (en) 2018-03-15
AU2015221447B9 (en) 2017-07-20
SI2478907T1 (sl) 2021-08-31
KR20180003636A (ko) 2018-01-09
CY1115477T1 (el) 2017-01-04
WO2008024484A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
NO20091190L (no) Fremgangsmater og sammensetninger for behandling av kreft
Rehman et al. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Thakur et al. Abiraterone acetate in the treatment of prostate cancer
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
Lønning Pharmacology of new aromatase inhibitors
Sobral et al. Unravelling exemestane: From biology to clinical prospects
Chetrite et al. The selective estrogen enzyme modulator (SEEM) in breast cancer
ID26781A (id) Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer
NO20062679L (no) Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
Agarwal et al. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer
WO2010091299A3 (en) Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
Xiong et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
Dhondt et al. Abiraterone and spironolactone in prostate cancer: a combination to avoid
Hu et al. Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells
MX2010005119A (es) Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.
Fiandalo et al. Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
NO20075758L (no) Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin
Ingle et al. Aromatase inhibitors for therapy of advanced breast cancer
Zhang et al. The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo
Brueggemeier Aromatase inhibitors: new endocrine treatment of breast cancer
Xu et al. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells
MX2022001066A (es) Derivados de saponina con ventana terapeutica mejorada.
Aragon-Ching et al. Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application